Receive our newsletter – data, insights and analysis delivered to you
  1. News
November 17, 2021

Brigham and Women’s Hospital to begin trial for Alzheimer’s Disease vaccine

The trial will feature 16 subjects aged between 60 and 85 years and with early, symptomatic AD.

Brigham and Women’s Hospital in Boston, US, is set to commence a clinical trial of a new intranasal vaccine for the treatment of Alzheimer’s Disease (AD).

The new vaccine uses Protollin, which activates the immune system, and is being developed to prevent and slow the disease progression.

Made of proteins drawn from bacteria, Protollin activates white blood cells in the lymph nodes in the neck and sends them to the brain to clear beta-amyloid plaques.

The single ascending dose (SAD) trial will feature 16 subjects aged between 60 and 85 years and with early, symptomatic AD.

Enrolled from the Ann Romney Center, the participants will be given two doses of the vaccine with a one-week gap.

Brigham & Women’s Hospital Neurologic Diseases Ann Romney Center co-director Howard L Weiner said: “The launch of the first human trial of a nasal vaccine for Alzheimer’s is a remarkable milestone. Over the last two decades, we’ve amassed preclinical evidence suggesting the potential of this nasal vaccine for AD.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

“If clinical trials in humans show that the vaccine is safe and effective, this could represent a non-toxic treatment for people with Alzheimer’s, and it could also be given early to help prevent Alzheimer’s in people at risk. The immune system plays a very important role in all neurologic diseases.”

The primary goal of the Phase I trial will be to ascertain the safety and tolerability of the nasal vaccine.

The nasal Protollin’s effect on participants’ immune systems, including on white blood cells, will be measured by the researchers.

Brigham and Women’s Hospital Neurology professor Tanuja Chitnis said: “This vaccine harnesses a novel arm of the immune system to treat AD.

“Research in this area has paved the way for us to pursue a whole new avenue for potentially treating not only AD but also other neurodegenerative diseases.”

Jiangsu Nhwa Pharmaceutical (NHWA) and I-Mab Biopharma (I-Mab) are responsible for the development, manufacturing and marketing of the immune modulator Protollin.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU